These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1942 related articles for article (PubMed ID: 19359544)

  • 21. Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer.
    Zhan Y; Cao B; Qi Y; Liu S; Zhang Q; Zhou W; Xu D; Lu H; Sartor O; Kong W; Zhang H; Dong Y
    Int J Cancer; 2013 Nov; 133(9):2225-33. PubMed ID: 23575870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
    Richards J; Lim AC; Hay CW; Taylor AE; Wingate A; Nowakowska K; Pezaro C; Carreira S; Goodall J; Arlt W; McEwan IJ; de Bono JS; Attard G
    Cancer Res; 2012 May; 72(9):2176-82. PubMed ID: 22411952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells.
    Makkonen H; Kauhanen M; Jääskeläinen T; Palvimo JJ
    Mol Cell Endocrinol; 2011 Jan; 331(1):57-65. PubMed ID: 20728506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Miller M; Kunkler R
    Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.
    Lieberman R
    Am J Ther; 2013; 20(2):128-31. PubMed ID: 23466618
    [No Abstract]   [Full Text] [Related]  

  • 29. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
    Scher HI; Beer TM; Higano CS; Anand A; Taplin ME; Efstathiou E; Rathkopf D; Shelkey J; Yu EY; Alumkal J; Hung D; Hirmand M; Seely L; Morris MJ; Danila DC; Humm J; Larson S; Fleisher M; Sawyers CL;
    Lancet; 2010 Apr; 375(9724):1437-46. PubMed ID: 20398925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and biological characterization of a novel series of androgen receptor modulators.
    Zhou C; Wu G; Feng Y; Li Q; Su H; Mais DE; Zhu Y; Li N; Deng Y; Yang D; Wang MW
    Br J Pharmacol; 2008 May; 154(2):440-50. PubMed ID: 18414397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
    Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.
    Liu S; Qi Y; Ge Y; Duplessis T; Rowan BG; Ip C; Cheng H; Rennie PS; Horikawa I; Lustig AJ; Yu Q; Zhang H; Dong Y
    Mol Cancer Ther; 2010 Jul; 9(7):2016-25. PubMed ID: 20571066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
    Pertusati F; Ferla S; Bassetto M; Brancale A; Khandil S; Westwell AD; McGuigan C
    Eur J Med Chem; 2019 Oct; 180():1-14. PubMed ID: 31288149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models.
    Bordini J; Morisi F; Elia AR; Santambrogio P; Pagani A; Cucchiara V; Ghia P; Bellone M; Briganti A; Camaschella C; Campanella A
    Clin Cancer Res; 2020 Dec; 26(23):6387-6398. PubMed ID: 32928793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
    Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
    Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 98.